Mylan Inc.'s ANDA For Three Times Per Week Generic Copaxone?? 40 Mg/Ml Accepted For Filing By FDA
Mylan Inc. 's ANDA For Three Times Per Week Generic CopaxoneA 40 Mg/Ml Accepted For Filing By FDA /PRNewswire/ -- Mylan Inc. today announced that its abbreviated new drug application for a three times per week Glatiramer Acetate Injection 40 mg/mL has been accepted for filing by the U.S. Food and Drug Administration .
Wed Aug 27, 2014
Mylan: Deeply Undervalued On Unwarranted Approval Concerns
Mylan is a manufacturer of generic pharmaceuticals. It closed on Tuesday, August 25, 2014 at $48.30.
Mon Aug 25, 2014
Ready2Go(TM) Draft Winners Join Pro Football MVP Adrian Peterson in...
Mylan Specialty, the fully integrated specialty pharmaceutical business of Mylan Inc. , and pro football player and EpiPen Auto-Injector spokesperson Adrian Peterson today announced the three winners of the Ready2Go MVP Draft , a nationwide search to find kids who have potentially life-threatening allergies and are prepared to respond should a ... (more)
Apricus Biosciences: A Screaming Buy Or A Falling Knife?
The company has fallen 20% since the first launch even though the short rate has also fallen, indicating investors are just walking away.
Fri Aug 22, 2014
Business Forum: The problem or a symptom?
The Obama administration urged lawmakers recently to pass legislation to contain the number of companies reincorporating overseas for tax purposes, commonly referred to as corporate inversion.
Mylan Launches First Generic Klor-ConA Extended-Release Tablets
Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product, which is indicated for the treatment of patients with hypokalemia, with or without metabolic alkalosis; in digitalis intoxication; and in patients with hypokalemic familial periodic paralysis.
Wed Aug 20, 2014
New Drug Launches, Technical Updates, New Facility, Clinical Trials...
Today, Analysts Review released its research reports regarding Covidien PLC , Mylan, Inc. , Baxter International Inc. , Achillion Pharmaceuticals, Inc. and Perrigo Company PLC .
Tue Aug 19, 2014
Mylan Launches Generic Precedexa Injection - Another Key Product Approval
Mylan yesterday received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product, which is indicated for the sedation of non-intubated patients prior to and/or during surgical and other procedures, and began shipping immediately.
Mon Aug 11, 2014
Mylan announces launch of Capecitabine Tablets USP, 150 mg and 500 mg
Mylan Inc. today announced that it has launched Capecitabine Tablets USP, 150 mg and 500 mg, the generic version of Genentech's Xeloda Tablets.
The Long Case For Mylan
After declining 20% from all-time highs in February, analysts are finally chasing Mylan by downgrading price targets for the year, which has proven to be a classic contrarian indicator.
Fri Aug 08, 2014
Nasdaq 100 Movers: MYL, NVDA
In early trading on Friday, shares of NVIDIA topped the list of the day's best performing components of the Nasdaq 100 index, trading up 7.2%.
RBC Capital Downgrades Mylan to Sector Perform
Mylan opened at 46.49 on Friday. Mylan has a 52 week low of $34.46 and a 52 week high of $57.52.
Thu Aug 07, 2014
Investor's Business Daily
Novo Nordisk, Mylan Miss Views; Mallinckrodt Beats
Earnings reports from specialty drugmakers continued to roll in Thursday, as two leading stocks stumbled in the early going on the stock market today .
Stock Market Today: August 7, 2014
Stocks to Watch from The Survey : Today is set to be another busy day on Wall Street, with investors digesting a slew of earnings reports.
Mylan profit down as expenses rise
Mylan Inc.'s profit dropped in the second quarter as expenses rose despite an 8 percent jump in revenue, and the company narrowed its earnings and revenue guidance for the full year.
Wed Aug 06, 2014
Tue Aug 05, 2014
Mylan: Buy, Sell, Or Hold
With a PEG close to 1.0 and a discounted earnings model that shows Mylan to be fairly valued, I consider the stock a hold at this point.
Sun Aug 03, 2014
Laws, loopholes can test private, public ties
Just ask Sen. Joe Manchin, D-W.Va., who opposes corporate tax inversions even as Mylan, the pharmaceutical company where his daughter Heather Bresch is CEO, is using them to lessen its tax burden.